Investment Thesis
Bone Biologics is a pre-revenue or near-complete revenue collapse company with zero gross profit, massive operating losses, and severely negative cash flow generation. The company is rapidly burning through its cash reserves ($5.3M) at approximately $2.7M annually with no clear path to profitability or sustainable operations.
Strengths
- Strong liquidity position with $5.3M cash and 13.85x current ratio
- Minimal debt burden with zero long-term debt provides financial flexibility
- Positive stockholders equity of $5.4M and conservative capital structure
Risks
- Operating cash flow of -$2.7M annually indicates cash will deplete in ~2 years at current burn rate
- Complete revenue collapse (100% YoY decline) suggests business model failure or operational discontinuation
- Negative operating margin of -1,268,604% demonstrates inability to achieve profitability with current revenue base
- Dilution risk evident from worsening EPS despite net income improvement, indicating significant equity issuance
- No gross profit generation suggests fundamental product viability or market demand issues
Key Metrics to Watch
- Operating cash flow trend and cash runway remaining
- Revenue stabilization or return to meaningful sales levels
- Gross margin recovery once revenue reaches viable levels
- Additional equity dilution and insider activity patterns
Financial Metrics
Revenue
255.0
Net Income
-3.1M
EPS (Diluted)
$-2.65
Free Cash Flow
-2.7M
Total Assets
5.8M
Cash
5.3M
Profitability Ratios
Gross Margin
0.0%
Operating Margin
-1,268,604.7%
Net Margin
-1,219,212.2%
ROE
-57.8%
ROA
-53.6%
FCF Margin
-1,055,550.6%
Balance Sheet & Liquidity
Current Ratio
13.85x
Quick Ratio
13.85x
Debt/Equity
0.00x
Debt/Assets
7.2%
Interest Coverage
-2.60x
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-20T17:44:10.907234 |
Data as of: 2025-12-31 |
Powered by Claude AI